<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34002281</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>268</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Navigating migraine care through the COVID-19 pandemic: an update.</ArticleTitle><Pagination><StartPage>4388</StartPage><EndPage>4395</EndPage><MedlinePgn>4388-4395</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-021-10610-w</ELocationID><Abstract><AbstractText>The worldwide treatment gap for migraine before COVID-19 inevitably widens as attention focuses on an international emergency. Migraine hits people particularly in their early and middle years, potentially reduces quality of life and productivity, and remains a common emergency presentation. This article examines the impact of COVID-19 on migraine, and changing aspects of migraine care during and after the pandemic. Many risk factors for severe COVID-19-older age, male gender, cardiac and respiratory diseases, diabetes, obesity, and immunosuppression-are less frequent in migraineurs. Telemedicine is effective for migraine follow-up, and needs ongoing evaluation. Most migraine treatments can start or continue in acute COVID-19, with care to avoid drug interactions. Close contact procedures (botulinum toxin, acupuncture and steroid injections) are avoided in lockdown or in the vulnerable. Secondary effects of COVID-19, including long COVID and its economic impact, are probably equal or greater in people with migraine. Migraine and other long-term conditions need adequate resourcing to prevent personal, social and economic suffering. Treating migraine, a sequel of COVID, potentially reduces the impact of long COVID.</AbstractText><CopyrightInformation>&#xa9; 2021. Crown.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Angus-Leppan</LastName><ForeName>Heather</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7004-3848</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK. heather.angus-leppan@nhs.net.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Royal Free London NHS Foundation Trust, Pond Street, London, NW32QG, UK. heather.angus-leppan@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guiloff</LastName><ForeName>Angelica E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Northern Medical Centre, Archway, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barts and the London School of Medicine and Dentistry, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benson</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Crouch Hall Road Surgery, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guiloff</LastName><ForeName>Roberto J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Chile, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Imperial College Healthcare NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008881" MajorTopicYN="Y">Migraine Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CGRP antagonists</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Headache</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Migraine</Keyword><Keyword MajorTopicYN="N">Telemedicine</Keyword></KeywordList><CoiStatement>HAL reports research support from National Institute for Health Research (NIHR), Epilepsy Action and Royal Free Charity, and Honoraria from Eisai, Sanofi and UCB unrelated to this work. AG KB and RJG have nothing to report. None of us have been involved in, or paid for, any CGRP-antagonist related work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>18</Day><Hour>7</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34002281</ArticleId><ArticleId IdType="pmc">PMC8128091</ArticleId><ArticleId IdType="doi">10.1007/s00415-021-10610-w</ArticleId><ArticleId IdType="pii">10.1007/s00415-021-10610-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The Work Foundation. Migraine&#x2019;s impact on employment in Europe. https://www.lancaster.ac.uk/work-foundation/?wp-content/uploads/2018/04/Society%e2%80%99s-headache-the-socioeconomic-impact-of-migraine.-Work-Foundation.pdf. Accessed Nov 2020</Citation></Reference><Reference><Citation>Global Burden of Disease Headache Collaborators Global, regional, and national burden of migraine and tension-type headache, 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954&#x2013;976. doi: 10.1016/S1474-4422(18)30322-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30322-3</ArticleId><ArticleId IdType="pmc">PMC6191530</ArticleId><ArticleId IdType="pubmed">30353868</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS England (2020) Improved NHS migraine care to save thousands of hospital stays. https://www.england.nhs.uk/2020/01/improved-nhs-migraine-care/. Accessed Dec 2020</Citation></Reference><Reference><Citation>Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19(1):115. doi: 10.1186/s10194-018-0946-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-018-0946-z</ArticleId><ArticleId IdType="pmc">PMC6755592</ArticleId><ArticleId IdType="pubmed">30482181</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation. Headache disorders. https://www.who.int/news-room/fact-sheets/detail/headache-disorders. Accessed Jan 2021</Citation></Reference><Reference><Citation>World Health Organisation. Rapid assessment of service delivery for NCDs during the COVID-19 pandemic. https://www.who.int/publications/m/item/rapid-assessment-of-service-delivery-for-ncds-during-the-covid-19-pandemic. Accessed Mar 2021</Citation></Reference><Reference><Citation>Bolay H, Ozge A, Uluduz D, et al. Are migraine patients at increased risk for symptomatic coronavirus disease 2019 due to shared comorbidities? Headache. 2020;60(10):2508&#x2013;2521. doi: 10.1111/head.13998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.13998</ArticleId><ArticleId IdType="pubmed">33124044</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi: 10.1136/bmj.m1985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1985</ArticleId><ArticleId IdType="pmc">PMC7243036</ArticleId><ArticleId IdType="pubmed">32444460</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430&#x2013;436. doi: 10.1038/s41586-020-2521-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner TJ, Scher AI, Stewart WF, et al. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003;23(7):519&#x2013;527. doi: 10.1046/j.1468-2982.2003.00568.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1468-2982.2003.00568.x</ArticleId><ArticleId IdType="pubmed">12950377</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelaye B, Sacco S, Brown WJ, et al. Body composition status and the risk of migraine: a meta-analysis. Neurology. 2017;88(19):1795&#x2013;1804. doi: 10.1212/WNL.0000000000003919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003919</ArticleId><ArticleId IdType="pmc">PMC5419981</ArticleId><ArticleId IdType="pubmed">28404807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurth T, Winter AC, Eliassen AH, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016;353:i2610. doi: 10.1136/bmj.i2610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i2610</ArticleId><ArticleId IdType="pmc">PMC4887613</ArticleId><ArticleId IdType="pubmed">27247281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343&#x2013;349. doi: 10.1212/01.wnl.0000252808.97649.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000252808.97649.21</ArticleId><ArticleId IdType="pubmed">17261680</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus-Leppan H. Migraine: mimics, borderlands and chameleons. Pract Neurol. 2013;13(5):308&#x2013;318. doi: 10.1136/practneurol-2012-000502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/practneurol-2012-000502</ArticleId><ArticleId IdType="pubmed">23906594</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus-Leppan H, Saatci D, Sutcliffe A, et al. Abdominal migraine. BMJ. 2018;360:k179. doi: 10.1136/bmj.k179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k179</ArticleId><ArticleId IdType="pubmed">29459383</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683&#x2013;690. doi: 10.1001/jamaneurol.2020.1127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 2020;26(7):1037&#x2013;1040. doi: 10.1038/s41591-020-0916-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0916-2</ArticleId><ArticleId IdType="pmc">PMC7751267</ArticleId><ArticleId IdType="pubmed">32393804</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinzon RT, Wijaya VO, Buana RB, et al. Neurologic characteristics in coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Front Neurol. 2020;11:565. doi: 10.3389/fneur.2020.00565.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00565</ArticleId><ArticleId IdType="pmc">PMC7273516</ArticleId><ArticleId IdType="pubmed">32574250</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus-Leppan H. Headache: basic trial designs, sample sizes and pitfalls. In: Guiloff RJ, editor. Clinical trials in neurology. London: Springer; 2001. pp. 279&#x2013;290.</Citation></Reference><Reference><Citation>Planchuelo-Gomez A, Trigo J, de Luis-Garcia R, et al. Deep phenotyping of headache in hospitalized COVID-19 patients via principal component analysis. Front Neurol. 2020;11:583870. doi: 10.3389/fneur.2020.583870.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.583870</ArticleId><ArticleId IdType="pmc">PMC7773780</ArticleId><ArticleId IdType="pubmed">33391152</ArticleId></ArticleIdList></Reference><Reference><Citation>Uygun O, Ertas M, Ekizoglu E, et al. Headache characteristics in COVID-19 pandemic-a survey study. J Headache Pain. 2020;21(1):121. doi: 10.1186/s10194-020-01188-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-020-01188-1</ArticleId><ArticleId IdType="pmc">PMC7552597</ArticleId><ArticleId IdType="pubmed">33050880</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hashel JY, Ismail II. Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study. J Headache Pain. 2020;21(1):115. doi: 10.1186/s10194-020-01183-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-020-01183-6</ArticleId><ArticleId IdType="pmc">PMC7513457</ArticleId><ArticleId IdType="pubmed">32972360</ArticleId></ArticleIdList></Reference><Reference><Citation>Membrilla JA, de Lorenzo I, Sastre M, et al. Headache as a cardinal symptom of coronavirus disease 2019: a cross-sectional study. Headache. 2020;60(10):2176&#x2013;2191. doi: 10.1111/head.13967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.13967</ArticleId><ArticleId IdType="pmc">PMC7646273</ArticleId><ArticleId IdType="pubmed">32989732</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiloff RJ, Fruns M. Limb pain in migraine and cluster headache. JNNP. 1988;51(8):1022&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1033109</ArticleId><ArticleId IdType="pubmed">3216204</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu A, Menon S, Colson NJ, et al. Analysis of the MTHFR C677T variant with migraine phenotypes. BMC Res Notes. 2010;3:213. doi: 10.1186/1756-0500-3-213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-0500-3-213</ArticleId><ArticleId IdType="pmc">PMC2919563</ArticleId><ArticleId IdType="pubmed">20663228</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M, Nakamoto M, Crocker J, et al. Early impact of the COVID-19 pandemic on outpatient migraine care in Hawaii: results of a quality improvement survey. Headache. 2021;61(1):149&#x2013;156. doi: 10.1111/head.14030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.14030</ArticleId><ArticleId IdType="pubmed">33316097</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas M, Katikireddi SV, Taulbut M, et al. Mitigating the wider health effects of covid-19 pandemic response. BMJ. 2020;369:m1557. doi: 10.1136/bmj.m1557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1557</ArticleId><ArticleId IdType="pmc">PMC7184317</ArticleId><ArticleId IdType="pubmed">32341002</ArticleId></ArticleIdList></Reference><Reference><Citation>Tommasi M, Toro F, Arno S, et al. Physical and psychological impact of the phase one lockdown for COVID-19 on Italians. Front Psychol. 2020;11:563722. doi: 10.3389/fpsyg.2020.563722.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2020.563722</ArticleId><ArticleId IdType="pmc">PMC7773646</ArticleId><ArticleId IdType="pubmed">33391079</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhagen IE, van Casteren DS, de Vries LS, et al. Effect of lockdown during COVID-19 on migraine: a longitudinal cohort study. Cephalagia. 2021 doi: 10.1177/0333102420981739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0333102420981739</ArticleId><ArticleId IdType="pmc">PMC8166402</ArticleId><ArticleId IdType="pubmed">33430642</ArticleId></ArticleIdList></Reference><Reference><Citation>Delussi M, Gentile E, Coppola G, et al. Investigating the effects of COVID-19 quarantine in migraine: an observational cross-sectional study from the Italian National Headache Registry (RICe) Front Neurol. 2020;11:597881. doi: 10.3389/fneur.2020.597881.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.597881</ArticleId><ArticleId IdType="pmc">PMC7683429</ArticleId><ArticleId IdType="pubmed">33240213</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson V. Neurological telemedicine in the COVID-19 era. Nat Rev Neurol. 2021;17(2):73&#x2013;74. doi: 10.1038/s41582-020-00438-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00438-9</ArticleId><ArticleId IdType="pmc">PMC7703718</ArticleId><ArticleId IdType="pubmed">33257883</ArticleId></ArticleIdList></Reference><Reference><Citation>James HM, Papoutsi C, Wherton J, et al. Spread, scale-up, and sustainability of video consulting in health care: systematic review and synthesis guided by the NASSS framework. J Med Internet Res. 2021;23(1):e23775. doi: 10.2196/23775.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/23775</ArticleId><ArticleId IdType="pmc">PMC7837451</ArticleId><ArticleId IdType="pubmed">33434141</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtney E, Blackburn D, Reuber M. Neurologists' perceptions of utilising tele-neurology to practice remotely during the COVID-19 pandemic. Patient Educ Couns. 2021;104(3):452&#x2013;459. doi: 10.1016/j.pec.2020.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pec.2020.12.027</ArticleId><ArticleId IdType="pubmed">33478853</ArticleId></ArticleIdList></Reference><Reference><Citation>Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edn. In: Cephalalgia, vol 38, issue 1, pp 1&#x2013;211. doi: 10.1177/0333102417738202</Citation><ArticleIdList><ArticleId IdType="pubmed">29368949</ArticleId></ArticleIdList></Reference><Reference><Citation>Do TP, Remmers A, Schytz HW, et al. Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Neurology. 2019;92(3):134&#x2013;144. doi: 10.1212/WNL.0000000000006697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006697</ArticleId><ArticleId IdType="pmc">PMC6340385</ArticleId><ArticleId IdType="pubmed">30587518</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakerley BR, Mollan SP, Sinclair AJ. Idiopathic intracranial hypertension: update on diagnosis and management. Clin Med (Lond) 2020;20(4):384&#x2013;388. doi: 10.7861/clinmed.2020-0232.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0232</ArticleId><ArticleId IdType="pmc">PMC7385768</ArticleId><ArticleId IdType="pubmed">32675143</ArticleId></ArticleIdList></Reference><Reference><Citation>Safadi K, Kruger JM, Chowers I, et al. Ophthalmology practice during the COVID-19 pandemic. BMJ Open Ophthalmol. 2020;5(1):e000487. doi: 10.1136/bmjophth-2020-000487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjophth-2020-000487</ArticleId><ArticleId IdType="pmc">PMC7222613</ArticleId><ArticleId IdType="pubmed">32432169</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang YE, Cho EY, Choi HY, et al. Diagnostic neuroimaging in headache patients: a systematic review and meta-analysis. Psychiatry Investig. 2019;16(6):407&#x2013;417. doi: 10.30773/pi.2019.04.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.30773/pi.2019.04.11</ArticleId><ArticleId IdType="pmc">PMC6603699</ArticleId><ArticleId IdType="pubmed">31247699</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxford Centre for evidence based medicine (2011). www.cebm.net/ocebm-levels-of-evidence/. Accessed Nov 2020</Citation></Reference><Reference><Citation>NICE (2021) COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. https://www.nice.org.uk/advice/es23/chapter/Key-messages. Accessed Jan 2021</Citation></Reference><Reference><Citation>Maassen Van Den Brink A, de Vries T, Danser AHJ. Headache medication and the COVID-19 pandemic. J Headache Pain. 2020;21(1):38. doi: 10.1186/s10194-020-01106-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-020-01106-5</ArticleId><ArticleId IdType="pmc">PMC7183387</ArticleId><ArticleId IdType="pubmed">32334535</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JS, Alfajaro MM, Chow RD, et al. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection. J Virol. 2021 doi: 10.1128/JVI.00014-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00014-21</ArticleId><ArticleId IdType="pmc">PMC8092681</ArticleId><ArticleId IdType="pubmed">33441348</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepper SJ. Opioids should not be used in migraine. Headache. 2012;52(Suppl 1):30&#x2013;34. doi: 10.1111/j.1526-4610.2012.02140.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4610.2012.02140.x</ArticleId><ArticleId IdType="pubmed">22540203</ArticleId></ArticleIdList></Reference><Reference><Citation>Dublin S, Walker RL, Jackson ML, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. J Am Geriatr Soc. 2011;59(10):1899&#x2013;1907. doi: 10.1111/j.1532-5415.2011.03586.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2011.03586.x</ArticleId><ArticleId IdType="pmc">PMC3223721</ArticleId><ArticleId IdType="pubmed">22091503</ArticleId></ArticleIdList></Reference><Reference><Citation>Canel L, Zisimopoulou S, Besson M, et al. Topiramate-induced severe heatstroke in an adult patient: a case report. J Med Case Rep. 2016;10:95. doi: 10.1186/s13256-016-0835-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-016-0835-5</ArticleId><ArticleId IdType="pmc">PMC4831160</ArticleId><ArticleId IdType="pubmed">27075033</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan HS, Frere Z, Krishnamoorthy V, et al. Association of gabapentinoid utilization with postoperative pulmonary complications in gynecologic surgery: a retrospective cohort study. Curr Med Res Opin. 2021 doi: 10.1080/03007995.2021.1900092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2021.1900092</ArticleId><ArticleId IdType="pubmed">33685298</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Carnahan RM, Chen H, et al. Anticholinergic medication use and risk of pneumonia in elderly adults: a nested case-control study. J Am Geriatr Soc. 2016;64(2):394&#x2013;400. doi: 10.1111/jgs.13932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.13932</ArticleId><ArticleId IdType="pubmed">26889844</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackey K, Kansagara D, Vela K. Update Alert 7: risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. Ann Intern Med. 2021;174(2):W25&#x2013;W29. doi: 10.7326/L20-1446.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/L20-1446</ArticleId><ArticleId IdType="pmc">PMC7791405</ArticleId><ArticleId IdType="pubmed">33395346</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese G, Benson L, Sundstrom J, et al. Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis. Eur J Heart Fail. 2021;23(3):476&#x2013;485. doi: 10.1002/ejhf.2060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2060</ArticleId><ArticleId IdType="pmc">PMC7753665</ArticleId><ArticleId IdType="pubmed">33222412</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller S, Sinclair AJ, Davies B, et al. Neurostimulation in the treatment of primary headaches. Pract Neurol. 2016;16(5):362&#x2013;375. doi: 10.1136/practneurol-2015-001298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/practneurol-2015-001298</ArticleId><ArticleId IdType="pmc">PMC5036247</ArticleId><ArticleId IdType="pubmed">27152027</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharaei H, Diwan S. COVID-19 pandemic: implications on interventional pain practice-a narrative review. Pain Physician. 2020;23(4S):S311&#x2013;S318.</Citation><ArticleIdList><ArticleId IdType="pubmed">32942791</ArticleId></ArticleIdList></Reference><Reference><Citation>Negro A, Delaruelle Z, Ivanova TA, et al. Headache and pregnancy: a systematic review. J Headache Pain. 2017;18(1):106. doi: 10.1186/s10194-017-0816-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-017-0816-0</ArticleId><ArticleId IdType="pmc">PMC5648730</ArticleId><ArticleId IdType="pubmed">29052046</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupi C, Negro A, Gambassi E, et al. Medicines for headache before and during pregnancy: a retrospective cohort study (ATENA study) Neurol Sci. 2020 doi: 10.1007/s10072-020-04702-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04702-0</ArticleId><ArticleId IdType="pmc">PMC8043957</ArticleId><ArticleId IdType="pubmed">32968869</ArticleId></ArticleIdList></Reference><Reference><Citation>Naasani I. COMPARE analysis, a bioinformatic approach to accelerate drug repurposing against Covid-19 and other emerging epidemics. SLAS Discov. 2021;26(3):345&#x2013;351. doi: 10.1177/2472555220975672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2472555220975672</ArticleId><ArticleId IdType="pmc">PMC8940772</ArticleId><ArticleId IdType="pubmed">33267713</ArticleId></ArticleIdList></Reference><Reference><Citation>Unal G, Turan B, Balcioglu YH. Immunopharmacological management of COVID-19: potential therapeutic role of valproic acid. Med Hypotheses. 2020;143:109891. doi: 10.1016/j.mehy.2020.109891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109891</ArticleId><ArticleId IdType="pmc">PMC7255327</ArticleId><ArticleId IdType="pubmed">32498007</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt B, Sutton NR, Wang Z, et al. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. Eur J Pharmacol. 2021;898:173988. doi: 10.1016/j.ejphar.2021.173988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.173988</ArticleId><ArticleId IdType="pmc">PMC7923868</ArticleId><ArticleId IdType="pubmed">33667455</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherian SS, Agrawal M, Basu A, et al. Perspectives for repurposing drugs for the coronavirus disease 2019. Indian J Med Res. 2020;151(2 &amp; 3):160&#x2013;171. doi: 10.4103/ijmr.IJMR_585_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmr.IJMR_585_20</ArticleId><ArticleId IdType="pmc">PMC7357399</ArticleId><ArticleId IdType="pubmed">32317408</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamurthy S, Lockey RF, Kolliputi N, et al. Soluble ACE2 as a potential therapy for COVID-19. Am J Physiol Cell Physiol. 1993;30(3):C279&#x2013;C281. doi: 10.1152/ajpcell.00478.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00478.2020</ArticleId><ArticleId IdType="pmc">PMC7938633</ArticleId><ArticleId IdType="pubmed">33502950</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875&#x2013;879. doi: 10.1038/nm1267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1267</ArticleId><ArticleId IdType="pmc">PMC7095783</ArticleId><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy VL, Koupenova M, Shah RV. ACEing COVID-19: a role for angiotensin axis inhibition in SARS-CoV-2 infection? Circ Res. 2020;126(12):1682&#x2013;1684. doi: 10.1161/CIRCRESAHA.120.317174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317174</ArticleId><ArticleId IdType="pmc">PMC7274880</ArticleId><ArticleId IdType="pubmed">32302248</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandasamy M. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19. Med Drug Discov. 2020;6:100042. doi: 10.1016/j.medidd.2020.100042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medidd.2020.100042</ArticleId><ArticleId IdType="pmc">PMC7189194</ArticleId><ArticleId IdType="pubmed">32352081</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation. WHO Living guideline: Drugs to prevent COVID-19 [January 2021].</Citation></Reference><Reference><Citation>Gelfand AA, Poland G. Migraine treatment and COVID-19 vaccines: no cause for concern. Headache. 2021 doi: 10.1111/head.14086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.14086</ArticleId><ArticleId IdType="pmc">PMC8013648</ArticleId><ArticleId IdType="pubmed">33543775</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwedt TJ, Hentz JG, Sahai-Srivastava S, et al. Headache characteristics and burden from chronic migraine with medication overuse headache: cross-sectional observations from the medication overuse treatment strategy trial. Headache. 2021;61(2):351&#x2013;362. doi: 10.1111/head.14056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.14056</ArticleId><ArticleId IdType="pubmed">33432635</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Lasaosa S, Porta-Etessam J. OnabotulinumtoxinA infiltration and nerve blocks in patients with headache and neuralgia: safety recommendations to prevent SARS-CoV-2 infection. Neurologia. 2020;35(5):291&#x2013;294. doi: 10.1016/j.nrl.2020.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nrl.2020.05.004</ArticleId><ArticleId IdType="pmc">PMC7221361</ArticleId><ArticleId IdType="pubmed">32410765</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta-Etessam J, Gonzalez-Garcia N, Matias-Guiu JA, et al. Should we adapt the prescription criteria for specific treatments for migraine due to the COVID-19 pandemic? Headache. 2020;60(7):1448&#x2013;1449. doi: 10.1111/head.13880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.13880</ArticleId><ArticleId IdType="pmc">PMC7307117</ArticleId><ArticleId IdType="pubmed">32526038</ArticleId></ArticleIdList></Reference><Reference><Citation>Caronna E, Ballve A, Llaurado A, et al. Headache: a striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia. 2020;40(13):1410&#x2013;1421. doi: 10.1177/0333102420965157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0333102420965157</ArticleId><ArticleId IdType="pmc">PMC7645597</ArticleId><ArticleId IdType="pubmed">33146036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Res Sq. 2021 doi: 10.21203/rs.3.rs-266574/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-266574/v1</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozen TD. Daily persistent headache after a viral illness during a worldwide pandemic may not be a new occurrence: lessons from the 1890 Russian/Asiatic flu. Cephalalgia. 2020;40(13):1406&#x2013;1409. doi: 10.1177/0333102420965132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0333102420965132</ArticleId><ArticleId IdType="pmc">PMC7645599</ArticleId><ArticleId IdType="pubmed">33146034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindran MK, Zheng Y, Timbol C, et al. Migraine headaches in chronic fatigue syndrome (CFS): comparison of two prospective cross-sectional studies. BMC Neurol. 2011;11:30. doi: 10.1186/1471-2377-11-30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-11-30</ArticleId><ArticleId IdType="pmc">PMC3058027</ArticleId><ArticleId IdType="pubmed">21375763</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>